Zobrazit v EDS

Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer's Disease

Uloženo v:
Podrobná bibliografie
Název: Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer's Disease
Autoři: Qingfeng Wen, Mandy Melissa Jane Wittens, Sebastiaan Engelborghs, Marcel H. M. van Herwijnen, Maria Tsamou, Erwin Roggen, Bert Smeets, Julian Krauskopf, Jacco Jan Briedé
Přispěvatelé: Communication Sciences, FORMER_Neuroprotection & Neuromodulation, Clinical sciences, Neurology, Neuroprotection & Neuromodulation
Zdroj: ACS Chem Neurosci
ACS chemical neuroscience
Informace o vydavateli: American Chemical Society (ACS), 2024.
Rok vydání: 2024
Témata: Alzheimer Disease/diagnosis, 2. Zero hunger, Amyloid beta-Peptides, Cognitive Dysfunction/diagnosis, biomarkers, Neuroimaging, tau Proteins, miR-145, microRNAs, 3. Good health, Chemistry, Phosphatidylinositol 3-Kinases, MicroRNAs, Alzheimer Disease, Humans, Cognitive Dysfunction, Human medicine, PI3K/AKT signaling, Biology, Alzheimer's disease, Biomarkers
Popis: Alzheimer's disease (AD) is the most common cause of dementia. New strategies for the early detection of MCI and sporadic AD are crucial for developing effective treatment options. Current techniques used for diagnosis of AD are invasive and/or expensive, so they are not suitable for population screening. Cerebrospinal fluid (CSF) biomarkers such as amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau181 (P-tau181) levels are core biomarkers for early diagnosis of AD. Several studies have proposed the use of blood-circulating microRNAs (miRNAs) as potential novel early biomarkers for AD. We therefore applied a novel approach to identify blood-circulating miRNAs associated with CSF biomarkers and explored the potential of these miRNAs as biomarkers of AD. In total, 112 subjects consisting of 28 dementia due to AD cases, 63 MCI due to AD cases, and 21 cognitively healthy controls were included. We identified seven Aβ1-42-associated plasma miRNAs, six P-tau181-associated plasma miRNAs, and nine Aβ1-42-associated serum miRNAs. These miRNAs were involved in AD-relevant biological processes, such as PI3K/AKT signaling. Based on this signaling pathway, we constructed an miRNA-gene target network, wherein miR-145-5p has been identified as a hub. Furthermore, we showed that miR-145-5p performs best in the prediction of both AD and MCI. Moreover, miR-145-5p also improved the prediction performance of the mini-mental state examination (MMSE) score. The performance of this miRNA was validated using different datasets including an RT-qPCR dataset from plasma samples of 23 MCI cases and 30 age-matched controls. These findings indicate that blood-circulating miRNAs that are associated with CSF biomarkers levels and specifically plasma miR-145-5p alone or combined with the MMSE score can potentially be used as noninvasive biomarkers for AD or MCI screening in the general population, although studies in other AD cohorts are necessary for further validation.
Druh dokumentu: Article
Other literature type
Jazyk: English
ISSN: 1948-7193
DOI: 10.1021/acschemneuro.3c00740
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38407050
https://cris.maastrichtuniversity.nl/en/publications/a26f4577-8e2b-4ffc-a551-7722cf3355b8
https://doi.org/10.1021/acschemneuro.3c00740
https://hdl.handle.net/10067/2048220151162165141
https://repository.uantwerpen.be/docstore/d:irua:22763
https://biblio.vub.ac.be/vubir/(1d8416b2-28cc-4886-81f8-ae6c496fdddd).html
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (http://creativecommons.org/licenses/by/4.0/).
Přístupové číslo: edsair.doi.dedup.....8ccf280e9faf84802dc6bde887582753
Databáze: OpenAIRE
Popis
Abstrakt:Alzheimer's disease (AD) is the most common cause of dementia. New strategies for the early detection of MCI and sporadic AD are crucial for developing effective treatment options. Current techniques used for diagnosis of AD are invasive and/or expensive, so they are not suitable for population screening. Cerebrospinal fluid (CSF) biomarkers such as amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau181 (P-tau181) levels are core biomarkers for early diagnosis of AD. Several studies have proposed the use of blood-circulating microRNAs (miRNAs) as potential novel early biomarkers for AD. We therefore applied a novel approach to identify blood-circulating miRNAs associated with CSF biomarkers and explored the potential of these miRNAs as biomarkers of AD. In total, 112 subjects consisting of 28 dementia due to AD cases, 63 MCI due to AD cases, and 21 cognitively healthy controls were included. We identified seven Aβ1-42-associated plasma miRNAs, six P-tau181-associated plasma miRNAs, and nine Aβ1-42-associated serum miRNAs. These miRNAs were involved in AD-relevant biological processes, such as PI3K/AKT signaling. Based on this signaling pathway, we constructed an miRNA-gene target network, wherein miR-145-5p has been identified as a hub. Furthermore, we showed that miR-145-5p performs best in the prediction of both AD and MCI. Moreover, miR-145-5p also improved the prediction performance of the mini-mental state examination (MMSE) score. The performance of this miRNA was validated using different datasets including an RT-qPCR dataset from plasma samples of 23 MCI cases and 30 age-matched controls. These findings indicate that blood-circulating miRNAs that are associated with CSF biomarkers levels and specifically plasma miR-145-5p alone or combined with the MMSE score can potentially be used as noninvasive biomarkers for AD or MCI screening in the general population, although studies in other AD cohorts are necessary for further validation.
ISSN:19487193
DOI:10.1021/acschemneuro.3c00740